Press Releases Keyword Search Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 October 8, 2026 Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia September 9, 2026 Editas Medicine Reports Inducement Grants to New Chief Medical Officer September 8, 2026 Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer September 1, 2026 Editas Medicine to Participate in Upcoming Investor Conferences August 5, 2026 Editas Medicine Announces Second Quarter 2026 Results and Business Updates August 4, 2026 Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. May 28, 2026 Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference May 26, 2026 Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering May 26, 2026 Editas Medicine Announces Proposed Public Offering May 26, 2026 Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress Pagination Current page 1 Page 2 Next page next › Last page last »
October 8, 2026 Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
August 4, 2026 Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
May 26, 2026 Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
